Cargando…
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918398/ https://www.ncbi.nlm.nih.gov/pubmed/27512681 http://dx.doi.org/10.2147/OV.S66081 |
_version_ | 1782439116443484160 |
---|---|
author | Nakashima, Hiroshi Nguyen, Tran Chiocca, Ennio Antonio |
author_facet | Nakashima, Hiroshi Nguyen, Tran Chiocca, Ennio Antonio |
author_sort | Nakashima, Hiroshi |
collection | PubMed |
description | Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi. |
format | Online Article Text |
id | pubmed-4918398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49183982016-08-10 Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy Nakashima, Hiroshi Nguyen, Tran Chiocca, Ennio Antonio Oncolytic Virother Review Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi. Dove Medical Press 2015-11-20 /pmc/articles/PMC4918398/ /pubmed/27512681 http://dx.doi.org/10.2147/OV.S66081 Text en © 2015 Nakashima et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Nakashima, Hiroshi Nguyen, Tran Chiocca, Ennio Antonio Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title_full | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title_fullStr | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title_full_unstemmed | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title_short | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
title_sort | combining hdac inhibitors with oncolytic virotherapy for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918398/ https://www.ncbi.nlm.nih.gov/pubmed/27512681 http://dx.doi.org/10.2147/OV.S66081 |
work_keys_str_mv | AT nakashimahiroshi combininghdacinhibitorswithoncolyticvirotherapyforcancertherapy AT nguyentran combininghdacinhibitorswithoncolyticvirotherapyforcancertherapy AT chioccaennioantonio combininghdacinhibitorswithoncolyticvirotherapyforcancertherapy |